4.6 Editorial Material

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis

Journal

ONCOIMMUNOLOGY
Volume 3, Issue 5, Pages -

Publisher

LANDES BIOSCIENCE
DOI: 10.4161/onci.28926

Keywords

Listeria; tumor-associated macrophages; ovarian cancer; immunotherapy; immunosuppression

Funding

  1. NCI NIH HHS [U54 CA151662, P30 CA023108] Funding Source: Medline
  2. NCRR NIH HHS [P30 RR032136] Funding Source: Medline
  3. NIAID NIH HHS [T32 AI007363] Funding Source: Medline

Ask authors/readers for more resources

A principal mechanism by which tumors evade immune-mediated elimination is through immunosuppression. Previous approaches to tumor immunotherapy have focused on modifying the immunosuppressive environment with immune checkpoint inhibitors, cytokine therapy, and other modalities with the intent to generate T-cell based antitumor immunity. We hypothesized that transformation of the suppressive ovarian cancer microenvironment could be achieved by introduction of the attenuated Delta actA/Delta inlB strain of Listeria monocytogenes. Delta actA/Delta inlB introduced into the microenvironment of the aggressive ID8-Defb29/Vegf-A murine ovarian carcinoma is preferentially phagocytosed by tumor-associated macrophages (TAMs) and reprograms that population from one of suppression to immunostimulation. TAMs in the peritoneum upregulated their co-stimulatory molecules CD80 and CD86, increased transcription of inflammatory cytokines, and downregulated transcription of suppressive effector molecules. Surprisingly, therapeutic benefit was not mediated by T-or NK-cell activity. Delta actA/Delta inlB-induced repolarization of TAMs activated direct tumor cell lysis via Nos2 production of nitric oxide. Modulation of the immunosuppressive nature of the ID8-Defb29/Vegf-A microenvironment, specifically by reprogramming of the TAM suppressive population from M2 to M1 polarization, is critical for our observed immune-mediated survival benefit.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available